આરતી ફાર્માલેબ્સ શેર કિંમત

Pharmaceuticals company Aarti Pharmalabs announced Q4FY26 & FY26 results Standalone Financial Highlights: Total Income: For Q4FY26, standalone total income was Rs 59,023.06 lakh, marking an increase of 38.65% QoQ from Rs 42,569.39 lakh in Q3FY26 and an increase of 11.45% YoY from Rs 52,958.57 lakh in Q4FY25. For FY26, total income stood at Rs 1,81,287.50 lakh, showing a growth of 1.61% YoY over Rs 1,78,414.86 lakh in FY25. Revenue from Operations (Net): Standalone revenue for Q4FY26 reached Rs 57,970.05 lakh, representing a growth of 36.32% QoQ from Rs 42,525.28 lakh and a growth of 9.46% YoY from Rs 52,962.37 lakh. Annual revenue for FY26 was Rs 1,79,755.17 lakh, a growth of 1.48% YoY from Rs 1,77,135.18 lakh. Profit Before Tax (PBT): For Q4FY26, standalone PBT was Rs 8,258.54 lakh, witnessing a growth of 44.01% QoQ compared to Rs 5,734.78 lakh in Q3FY26 and a decline of 27.24% YoY from Rs 11,350.20 lakh in Q4FY25. Annual standalone PBT for FY26 stood at Rs 23,423.90 lakh, down 30.36% YoY from Rs 33,634.11 lakh. Net Profit: Standalone net profit for Q4FY26 was Rs 6,203.07 lakh, up 44.52% QoQ from Rs 4,292.18 lakh and down 30.18% YoY from Rs 8,884.52 lakh. For FY26, net profit reached Rs 17,620.20 lakh, representing a decrease of 31.53% YoY compared to Rs 25,734.88 lakh in FY25. Earnings per Share (EPS): Basic EPS for FY26 was Rs 19.44, compared to Rs 28.39 in the previous year. Consolidated Financial Highlights: Total Income: Consolidated total income for Q4FY26 was Rs 59,069.56 lakh, representing an increase of 36.51% QoQ vs Rs 43,271.38 lakh and a 4.62% increase YoY vs Rs 56,463.66 lakh. For FY26, total income was Rs 1,82,918.89 lakh, a decrease of 13.86% YoY compared to Rs 2,12,350.04 lakh in FY25. Revenue from Operations (Net): Consolidated revenue for Q4FY26 was Rs 58,264.40 lakh, reflecting a 34.79% QoQ growth from Rs 43,227.27 lakh and a 3.35% increase YoY from Rs 56,377.70 lakh. Annual consolidated revenue for FY26 reached Rs 1,81,944.25 lakh, down 13.98% YoY from Rs 2,11,507.45 lakh. Profit Before Tax (PBT): For the quarter Q4FY26, consolidated PBT stood at Rs 8,167.86 lakh, showing an increase of 32.52% QoQ from Rs 6,163.57 lakh and a decline of 28.74% YoY from Rs 11,461.97 lakh. Annual consolidated PBT for FY26 was Rs 23,292.12 lakh, a decrease of 35.42% YoY vs Rs 36,068.95 lakh in FY25. Net Profit: Consolidated net profit for Q4FY26 reached Rs 6,112.41 lakh, marking a 29.96% QoQ increase from Rs 4,703.29 lakh and a 30.81% YoY decline from Rs 8,834.08 lakh. For FY26, annual net profit stood at Rs 17,470.73 lakh, down 35.87% YoY from Rs 27,240.48 lakh. Earnings per Share (EPS): Consolidated basic EPS for FY26 was Rs 19.27, compared to Rs 30.06 in FY25. Business Highlights: Segment Performance: The company operates primarily in a single business segment, which is "Pharmaceuticals". Dividend: The Board of Directors has recommended a final dividend of Rs 2 per equity share (40%) of face value Rs 5 each for the financial year 2025-26. Exceptional Items: The company recorded an incremental provision of Rs 279.49 lakh during the year ended March 31, 2026, on account of the impact of new labour codes. Foreign Exchange Impact: The company recognized a net mark-to-market (MTM) fair value loss of Rs 2,972.94 lakh for FY26 on target redemption forward contracts used for hedging export inflows. Corporate Designation: The Board designated Mr. Sachin Patil as Head - Exports and Mr. Rajendra Pagare as Head - Operations & Compliance as Senior Management Personnel effective May 25, 2026. Auditor Re-appointments: The company re-appointed Smt. Ketki D. Visariya as Cost Auditor and Manish Modi & Associates as Internal Auditor for FY27. Joint Venture: Ganesh Polychem Limited became a joint venture of the company effective April 1, 2025, following an addendum to the Shareholders' Agreement (SHA). Result PDF

• ટ્રેન્ડલાઇન
• 2 અઠવાડિયા 1 દિવસ પહેલાં

ફાર્માસ્યુટિકલ્સ કંપની આરતી ફાર્માલેબ્સે Q3FY26 પરિણામોની આવકની જાહેરાત કરી: Q3FY25 દરમિયાન ₹53,777.82 લાખ સામે ₹43,227.27 લાખ, -20% બદલો. પીબીટી: Q3FY25 દરમિયાન રૂ. 10,062.56 લાખ સામે રૂ. 6,286.88 લાખ, -38% બદલો. પીએટી: Q3FY25 દરમિયાન રૂ. 7,398.79 લાખ સામે રૂ. 4,795.56 લાખ, -35% બદલો. ઇપીએસ: Q3FY26 માટે ₹ 5.29. પરિણામની PDF

• ટ્રેન્ડલાઇન
• 4 મહિના પહેલાં

ફાર્માસ્યુટિકલ્સ કંપની આરતી ફાર્માલેબ્સે Q4FY25 અને નાણાંકીય વર્ષ 25 ના પરિણામોની જાહેરાત કરી Q4FY25 નાણાંકીય હાઇલાઇટ્સ: ઓપરેશનલ આવક: Q4FY24 દરમિયાન ₹5,058 મિલિયનની તુલનામાં ₹5,638 મિલિયન, ફેરફાર 11.5%. ઇબીઆઇટીડીએ: Q4FY24 દરમિયાન ₹ 1,175 મિલિયનની તુલનામાં ₹ 1,456 મિલિયન, બદલાવ 23.9%. EBITDA માર્જિન: Q4FY25 માટે 25.82%. પીબીટી: Q4FY24 દરમિયાન ₹ 957 મિલિયનની તુલનામાં ₹ 1,146 મિલિયન, બદલાવ 19.7%. પીએટી: Q4FY24 દરમિયાન ₹ 653 મિલિયનની તુલનામાં ₹ 883 મિલિયન, બદલો 35.2%. PAT માર્જિન: Q4FY25 માટે 15.66%. નાણાંકીય વર્ષ 25 નાણાંકીય વિશેષતાઓ: કાર્યકારી આવક: નાણાંકીય વર્ષ 24 દરમિયાન ₹ 18,526 મિલિયનની તુલનામાં ₹ 21,151 મિલિયન, ફેરફાર 14.2%. ઇબીઆઇટીડીએ: નાણાંકીય વર્ષ 24 દરમિયાન ₹ 3,860 મિલિયનની તુલનામાં ₹ 4,644 મિલિયન, ફેરફાર 20.3%. EBITDA માર્જિન: FY25 માટે 21.96%. પીબીટી: નાણાંકીય વર્ષ 24 દરમિયાન ₹ 3,005 મિલિયનની તુલનામાં ₹ 3,607 મિલિયન, ફેરફાર 20.0%. પીએટી: નાણાંકીય વર્ષ 24 દરમિયાન ₹ 2,169 મિલિયનની તુલનામાં ₹ 2,724 મિલિયન, ફેરફાર 25.6%. PAT માર્જિન: FY25 માટે 12.88%. પરિણામની PDF

• ટ્રેન્ડલાઇન
• 1 વર્ષ પહેલાં